Latigo Biotherapeutics, a Phase 3-ready biotech developing non-opioid, oral therapies for acute and chronic pain, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines targeting the Nav1.8 sodium channel. Its lead candidate, LTG-001, is an oral Nav1.8 inhibitor for moderate to severe acute pain, including postoperative pain, and recently reported positive topline data from a 343-patient abdominoplasty trial, meeting its primary SPID48 endpoint versus placebo. A placebo-controlled Phase 3 bunionectomy trial and an open-label Phase 3 safety trial are planned for the second half of 2026, with topline results expected in the second half of 2027. LTG-321, a second Nav1.8 candidate for chronic musculoskeletal pain starting with osteoarthritis, is in a Phase 2 proof-of-concept trial with results also expected in the second half of 2027. The company's earlier-stage pipeline includes LTG-418, a preclinical Nav1.8 inhibitor, along with additional discovery programs targeting other ion channels involved in pain transmission.
The Thousand Oaks, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol LTGO. Latigo Biotherapeutics filed confidentially on March 27, 2026. Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities are the joint bookrunners on the deal.
